Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its continuous glucose monitoring system. Trinity Biotech plc (NASDAQ ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech projects an annualized run rate of $20 million in EBITDASO and $75 million in revenues by Q2 2025, with a 20% sales increase and a $6.5 million EBITDA turnaround anticipated in 2025.

Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from Benzinga Pro. The company received ...

Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock. Trinity ...

StockNews.com cut shares of Trinity Biotech (NASDAQ:TRIB – Free Report) from a hold rating to a sell rating in a research report released on Thursday. Trinity Biotech Stock Up 1.6 % Shares of TRIB ...